TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi

TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data ...
The Manila Times

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary …

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing ...
Clinical Trials Arena

TG Therapeutics concludes enrolment in Phase III Briumvi trial

TG Therapeutics has completed enrolment in its Phase III trial investigating subcutaneous Briumvi in adults with RMS.
HR News

Rise of AI in Recruitment Creating Trust Gap Between Employers and Jobseekers, Study Finds

Artificial intelligence is rapidly transforming recruitment across the UK, but a growing trust gap is emerging between ...
The Manila Times

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months ...
Barron's

Hermes International S.C.A.

About Hermes International S.C.A. Hermes International SCA engages in the provision of textiles and apparel. Its activities include manufacturing, sale, and distribution of apparel products, such as ...